ProCE Banner Activity

Beware of the Troll: Preventing CMV After Solid Organ Transplantation

Clinical Thought

Here’s what I consider when selecting between universal prophylaxis and preemptive therapy to prevent CMV disease in high-risk solid transplant recipients.

 

Released: August 30, 2023

Share

Faculty

Hannah Imlay

Hannah Imlay, MD, MS

Assistant Professor 
Internal Medicine/Infectious Diseases 
University of Utah 
Salt Lake City, Utah 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA

Merck & Co., Inc., Rahway, NJ, USA

Disclosure

Primary Author

Hannah Imlay, MD, MS

Assistant Professor 
Internal Medicine/Infectious Diseases 
University of Utah 
Salt Lake City, Utah 

Hannah Imlay, MD, MS, has no relevant financial relationships to disclose.